Skip to main content

Korsana Biosciences, Inc.

KRSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001755237

No open-market purchases or sales by Korsana Biosciences, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $11.2M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Korsana Biosciences, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of KRSA: Q2 2021 compared with Q3 2021
MeasureQ2 2021Of which not filed for Q3 2021Q3 2021Change
Holders68262−4
Shares24.6M116.3K24.7M+191.6K (+0.8%)
Value$96.0M$454.0K$75.8M−$19.7M (−20.7%)

2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (10)

Institutions that held Korsana Biosciences, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to KRSA in Q3 2021
InstitutionSharesValue% of portfolio
Eversept Partners, LP371,955$1.14M0.09%
Franklin Resources Inc116,035$356.0K0.00%
Jacobs Levy Equity Management, Inc91,285$280.0K0.00%
Jump Financial, LLC52,000$160.0K0.01%
Tower Research Capital LLC (TRC)28,738$88.0K0.00%
Jane Street Group, LLC16,607$51.0K0.00%
Gerber Kawasaki Wealth & Investment Management2,046$6.00K0.00%
Total Clarity Wealth Management, Inc.1,500$5.00K0.00%
Belvedere Trading LLC156$00.00%
Advisor Group Holdings, Inc.12$00.00%

Sold out (14)

Institutions that held Korsana Biosciences, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Not filed for Q3 2021 yet (2)

Institutions that held Korsana Biosciences, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KRSA in Q2 2021 that haven't filed for Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
QS Investors, LLC116,035$453.0K
CWM, LLC297$1.00K